Wednesday, November 18, 2026

HOSPITAL SUPERBUG SURGES ACROSS EUROPE, INCLUDING CYPRUS





HOSPITAL SUPERBUG SURGES ACROSS EUROPE, INCLUDING CYPRUS - KNews 18/11

Drug-resistant Klebsiella bloodstream infections rose 72% across the EU from 2019 to 2025. Cyprus recorded about 21 cases per 100,000 people in 2025, nearly six times the regional rate.


In a report by Politico, Europe’s disease agency warned that a hospital superbug is spreading between patients and leaving doctors with fewer ways to treat it. The rate of bloodstream infections caused by a drug-resistant form of Klebsiella pneumoniae rose 72% between 2019 and 2025. The EU had set out to cut that rate by 5% by 2030.

The bacteria can live in the gut, which helps explain why they can be harder to contain than MRSA, another well-known hospital superbug. The form tracked in the report can withstand carbapenems, a class of antibiotics doctors turn to for serious infections when other drugs may fail. Some strains can also withstand newer antibiotics developed to treat them. Once the bacteria reach the bloodstream, the infection can be life-threatening.
The European Centre for Disease Prevention and Control is calling for stricter hand hygiene, proper use of gloves and other protective equipment, and thorough cleaning and disinfection of patient areas. The agency says faster genetic testing can also help hospitals work out whether infections are linked, giving them a chance to intervene sooner.

Europe’s record on drug resistance is mixed. MRSA bloodstream infections fell 19% between 2019 and 2025, exceeding the EU’s 2030 reduction target. Over the same period, bloodstream infections caused by a resistant form of E. coli rose 16.4%, and overall antibiotic use fell just 5%, against a target of 20%. Politico reported that EU pharmaceutical legislation expected to be signed in December includes incentives to develop new antibiotics.

What has happened in Cyprus?

Cyprus has documented these infections for years. A study of 175 patients treated for Klebsiella bloodstream infections at Nicosia General Hospital between 2014 and 2018 found that 13 had the form resistant to carbapenems. Those patients were more likely to have recently had surgery or to have hospital-associated pneumonia, though the group was too small for researchers to draw firm conclusions about risk factors.

The latest national figures show how much the problem has grown. The estimated rate in Cyprus climbed from 5.51 infections per 100,000 people in 2021 to 21.29 in 2025, the highest among EU and EEA countries in the report. The regional rate was 3.70 per 100,000. In a separate measure, 49.2% of the 366 Klebsiella samples tested in Cyprus in 2025 were resistant to carbapenems, up from 26.2% in 2021.

The national figures track how often the infections occur and which antibiotics the bacteria resist. They do not say how many patients recovered or died, where each patient picked up the infection, or whether the cases were linked to an outbreak at a particular hospital. For patients in Cyprus who develop one of these infections, the immediate concern is that doctors may have fewer effective antibiotics to choose from.